Will World's Largest HCV Population Have Access To Newest Treatments?
This article was originally published in PharmAsia News
Executive Summary
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources